China SFDA Offers Expanded Medical Device GCPs For Comment
This article was originally published in PharmAsia News
Containing comprehensive responsibilities for sponsors and ethics committees, a revised SFDA guideline on clinical trials for medical devices should be helpful for MNCs, but lawyers advise companies to review the draft carefully.
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.